Product
AD109
6 clinical trials
2 indications
Indication
obstructive sleep apneaIndication
Obstructive Sleep ApneaClinical trial
Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (LunAIRo Study)Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep ApneaStatus: Completed, Estimated PCD: 2022-07-20
Clinical trial
Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep ApneaStatus: Completed, Estimated PCD: 2021-05-28
Clinical trial
Phase 2 Randomized Double-Blind Placebo-Controlled 3-Period Single-Dose Crossover Study to Evaluate the Safety and Efficacy of Two Doses of AD-109 in Mild to Moderate Obstructive Sleep ApneaStatus: Completed, Estimated PCD: 2021-05-31
Clinical trial
Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide or SemaglutideStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study)Status: Recruiting, Estimated PCD: 2025-02-01